These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35727143)

  • 41. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    Taramasso L; Berruti M; Briano F; Di Biagio A
    AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
    Hocqueloux L; Menard A; Arvieux C; Joly V; Becker A; Chéret A; Duvivier C; Cabié A; Delpierre C; Allavena C;
    HIV Med; 2023 Aug; 24(8):925-932. PubMed ID: 37015896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.
    Moschopoulos CD; Protopapas K; Thomas K; Kavatha D; Papadopoulos A; Antoniadou A
    AIDS Res Hum Retroviruses; 2023 Feb; 39(2):68-75. PubMed ID: 36401506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients.
    Lagoutte-Renosi J; Flammang M; Chirouze C; Beck-Wirth G; Bozon F; Brunel AS; Drobacheff-Thiebaut MC; Foltzer A; Hustache-Mathieu L; Kowalczyk J; Michel C; Davani S; Muret P
    Curr HIV Res; 2021; 19(1):84-89. PubMed ID: 32838719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
    Ikeda M; Wakabayashi Y; Okamoto K; Yanagimoto S; Okugawa S; Moriya K
    AIDS Res Ther; 2021 May; 18(1):30. PubMed ID: 34044856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
    Surial B; Cavassini M; Calmy A; Fehr J; Stöckle M; Bernasconi E; Roth B; Fux CA; Kovari H; Furrer H; Rauch A; Wandeler G;
    BMC Infect Dis; 2019 Oct; 19(1):834. PubMed ID: 31601174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate- to tenofovir alafenamide-containing ART among individuals with HIV in Canada: A retrospective study.
    Shokoohi M; Gupta M; Crouzat F; Smith G; Kovacs C; Brunetta J; Chang B; Knox D; Acsai M; Merkley B; Giolma K; Fletcher D; Loutfy M
    Int J STD AIDS; 2021 Aug; 32(9):861-871. PubMed ID: 33890817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
    Teira R; Diaz-Cuervo H; Aragão F; Muñoz J; Galindo P; Merino M; de la Fuente B; Sepúlveda MA; Domingo P; García J; Castaño M; Ribera E; Geijo P; Romero A; Peraire J; Deig E; Roca B; Martínez E; Estrada V; Montero M; Berenguer J; Espinosa N
    HIV Res Clin Pract; 2021 Jun; 22(3):78-85. PubMed ID: 34410219
    [No Abstract]   [Full Text] [Related]  

  • 53. A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
    Lee SS; Havens JP; Sayles HR; O'Neill JL; Podany AT; Swindells S; Scarsi KK; Bares SH
    BMC Infect Dis; 2018 Jul; 18(1):310. PubMed ID: 29980192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
    Arribas JR; Thompson M; Sax PE; Haas B; McDonald C; Wohl DA; DeJesus E; Clarke AE; Guo S; Wang H; Callebaut C; Plummer A; Cheng A; Das M; McCallister S
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):211-218. PubMed ID: 28282300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenofovir alafenamide revisited.
    Di Perri G
    Infez Med; 2020 Dec; 28(4):525-533. PubMed ID: 33257626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
    Vergori A; Gagliardini R; Gianotti N; Gori A; Lichtner M; Saracino A; De Vito A; Cascio A; Di Biagio A; Monforte AD; Antinori A; Cozzi-Lepri A;
    Int J Antimicrob Agents; 2020 Dec; 56(6):106154. PubMed ID: 32919008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides.
    Mallon PWG; Brunet L; Fusco JS; Prajapati G; Beyer A; Fusco GP; Wohlfeiler MB
    Open Forum Infect Dis; 2022 Jan; 9(1):ofab621. PubMed ID: 35028335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study.
    Abe K; Imamura J; Sasaki A; Suzuki T; Kamio S; Obara T; Ito T
    J Pharm Health Care Sci; 2024 Feb; 10(1):13. PubMed ID: 38419093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
    Orkin C; Eron JJ; Rockstroh J; Podzamczer D; Esser S; Vandekerckhove L; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Opsomer M;
    AIDS; 2020 Apr; 34(5):707-718. PubMed ID: 31833849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.